Home›Stock Screener›Kabra Drugs›Financial Statements

Kabra Drugs Complete Financial Statements

12 Years of Data
2026 - 2015

In FY2026, Kabra Drugs (KABRADG) reported revenue ₹93 Cr, net profit ₹5 Cr and EPS ₹2.09, with a net profit margin of 5.4% and ROE of 16.7%. Full financial statements from FY2015 to FY2026 (12 years) — income statement, balance sheet and cash flow in ₹ Crores. Download as Excel or CSV. Analyse KABRADG shareholder distribution to track promoter, FII and institutional holdings.

Complete Financial Data Export

Profitability Ratios

Net Profit Margin 5.38% 2026 data
EBITDA Margin 5.38% 2026 data
Operating Margin 6.00% 2026 data
Return on Assets 5.81% 2026 data
Return on Equity 16.67% 2026 data

Balance Sheet Ratios

Equity Ratio 34.88% 2026 data
Asset Turnover 1.08 2026 data

KABRADG Revenue, Net Profit & EBITDA — Year-on-Year Growth

KABRADG YoY (March 2025 vs March 2026) — revenue +9200.0%, net profit +600.0%, EBITDA +600.0%, expenses +4250.0%. Also explore Kabra Drugs share price performance to track price trends across different timeframes.

Revenue Growth
+9200.0%
Year-over-Year
Net Profit Growth
+600.0%
Year-over-Year
EBITDA Growth
+600.0%
Year-over-Year
Expense Growth
+4250.0%
Year-over-Year
Assets Growth
+244.0%
Year-over-Year
Equity Growth
+20.0%
Year-over-Year
Financing Cash Flow Growth
+666.7%
Year-over-Year

KABRADG Income Statement — Revenue, EBITDA & Net Profit

Kabra Drugs revenue ₹93 Cr, EBITDA ₹5 Cr, net profit ₹5 Cr, EPS ₹2.09 (2026) — net profit margin 5.4%. For live price, earnings ratios and company overview, see Kabra Drugs stock price NSE.

Periods ₹ Crores
Particulars March 2026 March 2025 March 2024 March 2023 March 2022 March 2021 March 2020 March 2019 March 2018 March 2017 March 2016 March 2015
Revenue 93 1 0 0 0 0 0 0 2 8 10 8
Expenses 87 2 1 0 0 0 0 0 3 7 9 8
EBITDA 5 -1 -1 0 0 0 0 0 -1 1 1 0
Operating Profit Margin % 6.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -57.00% 6.00% 5.00% 5.00%
Depreciation 0 0 0 0 0 0 0 0 0 0 0 0
Interest 0 0 0 0 0 0 0 0 0 0 0 0
Profit Before Tax 6 -1 -1 0 0 0 0 0 -2 0 0 0
Tax 1 0 0 0 0 0 0 0 0 0 0 0
Net Profit 5 -1 -1 0 0 0 0 0 -2 0 0 0
Earnings Per Share (₹) 2.09 -0.99 -1.68 -0.77 -0.42 -0.41 -0.14 -0.38 -5.37 0.30 0.06 0.16

KABRADG Balance Sheet — Assets, Liabilities & Shareholders' Equity

KABRADG total assets ₹86 Cr, total equity ₹30 Cr, total liabilities ₹ Cr (2026) — ROE 16.7%.

Years Annual Data ₹ Crores
Particulars 2026 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015
ASSETS
Total Assets 86 25 5 1 1 1 1 2 2 6 9 9
Current Assets 84 25 5 1 1 1 1 1 2 4 6 6
Fixed Assets 1 0 0 0 0 0 0 0 0 3 3 3
Capital Work in Progress 0 0 0 0 0 0 0 0 0 0 0 0
Investments 0 0 0 0 0 0 0 0 0 0 0 0
Other Assets 0 25 5 1 1 1 1 1 2 4 6 6
LIABILITIES
Total Liabilities
Current Liabilities 0 0 0 0 0 0 0 0 0 1 2 3
Non-Current Liabilities
SHAREHOLDERS' EQUITY
Total Equity 30 25 1 -1 0 0 0 0 0 3 3 3
Share Capital 24 24 4 4 4 4 4 4 4 4 4 4
Reserves & Surplus 6 1 -6 -5 -5 -5 -4 -4 -4 -2 -2 -2

KABRADG Cash Flow Statement — Operating, Investing & Financing

Kabra Drugs operating cash flow ₹-5 Cr, investing ₹0 Cr, financing ₹23 Cr, net cash flow ₹19 Cr (2025).

Periods ₹ Crores
Particulars March 2025 March 2024 March 2023 March 2022 March 2021 March 2020 March 2019 March 2018 March 2017 March 2016 March 2015
Operating Activities -5 0 0 0 0 0 0 0 0 0 0
Investing Activities 0 0 0 0 0 0 0 2 0 0 0
Financing Activities 23 3 0 0 0 0 0 -1 0 0 1
Net Cash Flow 19 3 0 0 0 0 0 0 0 0 0